Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Wolff

Showing results (141-150 of 177) with videos related to

Pageof 18
Sort By:
The European Respiratory Journal|March 14, 2024
ERS/EBMT clinical practice guidelines on treatment of pulmonary chronic graft-<i>versus</i>-host disease in adultsSaskia Bos, John Murray, Monia Marchetti, et al.
The Lancet. Haematology|January 6, 2024
Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow TransplantationOlaf Penack, Monia Marchetti, Mahmoud Aljurf, et al.
Blood|May 5, 2025
Expansions of circulating plasmablasts producing commensal-reactive IgA antibodies are predictors for chronic GVHDKatharina Marie Habenicht, Jana Wanzek, Anna Bootz, et al.
Frontiers in Immunology|September 26, 2018
Increased Risk for Malignancies in 131 Affected <i>CTLA4</i> Mutation CarriersDavid Egg, Charlotte Schwab, Annemarie Gabrysch, et al.
Blood Advances|November 9, 2022
Reg3α concentrations at day of allogeneic stem cell transplantation predict outcome and correlate with early antibiotic useDaniela Weber, Markus Weber, Elisabeth Meedt, et al.
The New England Journal of Medicine|September 18, 2024
Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host DiseaseDaniel Wolff, Corey Cutler, Stephanie J Lee, et al.
Blood|February 2, 2021
Targeting of canonical WNT signaling ameliorates experimental sclerodermatous chronic graft-versus-host diseaseYun Zhang, Lichong Shen, Katja Dreißigacker, et al.
The Lancet. Haematology|March 5, 2025
Ask, do not tell: consulting a patient advisory board to understand unmet needs of patients with GVHD in EuropeHélène Schoemans, Elke Stienissen, Kathy Goris, et al.
Annals of Hematology|November 16, 2020
Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study GroupEsther Schuler, Eva-Maria Wagner-Drouet, Salem Ajib, et al.
Transplantation and Cellular Therapy|May 7, 2025
Changes in Chronic Graft-versus-Host Disease Treatment Over Time: A 15-Years Survey Within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and SwitzerlandAlexander Denk, Matthias Alexander Fante, Silke Heidenreich, et al.
Pageof 18

Showing results (141-150 of 177) with videos related to

Sort By:
Pageof 18
The European Respiratory Journal|March 14, 2024
ERS/EBMT clinical practice guidelines on treatment of pulmonary chronic graft-<i>versus</i>-host disease in adultsSaskia Bos, John Murray, Monia Marchetti, et al.
The Lancet. Haematology|January 6, 2024
Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow TransplantationOlaf Penack, Monia Marchetti, Mahmoud Aljurf, et al.
Blood|May 5, 2025
Expansions of circulating plasmablasts producing commensal-reactive IgA antibodies are predictors for chronic GVHDKatharina Marie Habenicht, Jana Wanzek, Anna Bootz, et al.
Frontiers in Immunology|September 26, 2018
Increased Risk for Malignancies in 131 Affected <i>CTLA4</i> Mutation CarriersDavid Egg, Charlotte Schwab, Annemarie Gabrysch, et al.
Blood Advances|November 9, 2022
Reg3α concentrations at day of allogeneic stem cell transplantation predict outcome and correlate with early antibiotic useDaniela Weber, Markus Weber, Elisabeth Meedt, et al.
The New England Journal of Medicine|September 18, 2024
Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host DiseaseDaniel Wolff, Corey Cutler, Stephanie J Lee, et al.
Blood|February 2, 2021
Targeting of canonical WNT signaling ameliorates experimental sclerodermatous chronic graft-versus-host diseaseYun Zhang, Lichong Shen, Katja Dreißigacker, et al.
The Lancet. Haematology|March 5, 2025
Ask, do not tell: consulting a patient advisory board to understand unmet needs of patients with GVHD in EuropeHélène Schoemans, Elke Stienissen, Kathy Goris, et al.
Annals of Hematology|November 16, 2020
Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study GroupEsther Schuler, Eva-Maria Wagner-Drouet, Salem Ajib, et al.
Transplantation and Cellular Therapy|May 7, 2025
Changes in Chronic Graft-versus-Host Disease Treatment Over Time: A 15-Years Survey Within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and SwitzerlandAlexander Denk, Matthias Alexander Fante, Silke Heidenreich, et al.
Pageof 18